KPTI Karyopharm Therapeutics Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

KPTI [NASD]

Karyopharm Therapeutics Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-2.92	Insider Own	1.90%	Shs Outstand	67.63M	Perf Week	-2.74%
Market Cap	1.37B	Forward P/E	-	EPS next Y	-1.39	Insider Trans	-21.32%	Shs Float	66.07M	Perf Month	9.04%
Income	-186.40M	PEG	-	EPS next Q	-0.57	Inst Own	91.03%	Short Float	21.92%	Perf Quarter	-6.62%
Sales	58.90M	P/S	23.24	EPS this Y	-2.60%	Inst Trans	21.24%	Short Ratio	8.12	Perf Half Y	-0.23%
Book/sh	2.46	P/B	7.79	EPS next Y	43.60%	ROA	-59.80%	Target Price	32.56	Perf Year	151.91%
Cash/sh	4.93	P/C	3.89	EPS next 5Y	-	ROE	-208.10%	52W Range	7.37 - 29.61	Perf YTD	0.00%
Dividend	-	P/FCF	-	EPS past 5Y	-5.80%	ROI	-118.50%	52W High	-35.26%	Beta	1.53
Dividend %	-	Quick Ratio	7.40	Sales past 5Y	182.10%	Gross Margin	94.50%	52W Low	160.11%	ATR	1.14
Employees	347	Current Ratio	7.50	Sales Q/Q	11601.90%	Oper. Margin	-	RSI (14)	51.91	Volatility	5.22% 6.58%
Optionable	Yes	Debt/Eq	1.12	EPS Q/Q	28.00%	Profit Margin	-	Rel Volume	0.82	Prev Close	18.85
Shortable	Yes	LT Debt/Eq	1.12	Earnings	May 05 BMO	Payout	-	Avg Volume	1.78M	Price	19.17
Recom	1.70	SMA20	2.65%	SMA50	1.35%	SMA200	10.38%	Volume	1,458,908	Change	1.70%

Jul-02-20

Initiated

Morgan Stanley

Overweight

$34

Mar-04-20

Initiated

Barclays

Overweight

$30

Jan-17-20

Downgrade

Wedbush

Outperform → Neutral

Jul-23-19

Upgrade

JP Morgan

Neutral → Overweight

$8 → $16

Jul-05-19

Reiterated

Robert W. Baird

Outperform

$15 → $25

Jul-05-19

Reiterated

H.C. Wainwright

Buy

$29 → $32

Mar-01-19

Downgrade

JP Morgan

Overweight → Neutral

$21 → $7

Feb-28-19

Reiterated

BofA/Merrill

Underperform

$15 → $5

Feb-27-19

Downgrade

BofA/Merrill

Neutral → Underperform

$15 → $5

Jan-03-19

Upgrade

BofA/Merrill

Underperform → Neutral

Dec-03-18

Initiated

B. Riley FBR

Buy

$23

Nov-09-18

Upgrade

Wedbush

Neutral → Outperform

$19

May-24-18

Downgrade

Wedbush

Outperform → Neutral

$20 → $19

Apr-02-18

Resumed

Leerink Partners

Outperform

$19

Nov-15-17

Resumed

H.C. Wainwright

Buy

$23

Sep-15-17

Initiated

RBC Capital Mkts

Outperform

$14

Sep-08-16

Reiterated

H.C. Wainwright

Buy

$15 → $16

Aug-30-16

Upgrade

Jefferies

Hold → Buy

Aug-18-16

Initiated

H.C. Wainwright

Buy

$15

Jun-28-16

Initiated

Robert W. Baird

Outperform

$16

Jul-01-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Jun-29-20 12:53PM	Top Small Cap Stocks for July 2020 Investopedia
Jun-24-20 07:00AM	Karyopharm Announces Publication of XPOVIO® (Selinexor) Phase 2b SADAL Study Results in The Lancet Haematology GlobeNewswire -5.79%
Jun-23-20 11:50AM	Karyopharm's Xpovio Gets FDA Accelerated Approval for DLBCL Zacks
Jun-22-20 11:25AM	Karyopharm Announces FDA Approval of XPOVIO® (selinexor) for the Treatment of Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) GlobeNewswire
Jun-21-20 02:53PM	The Week Ahead In Biotech: Karyopharm, Zogenix, Heron, Chiasma On The Radar Ahead Of FDA Decisions Benzinga
Jun-18-20 03:34PM	Karyopharm Therapeutics Inc (KPTI): Hedge Funds Taking Some Chips Off The Table Insider Monkey
Jun-12-20 03:58PM	Edited Transcript of KPTI earnings conference call or presentation 5-May-20 12:30pm GMT Thomson Reuters StreetEvents
07:00AM	Karyopharm Presents XPOVIO® (selinexor) and Eltanexor Data at the European Hematology Association 2020 Virtual Annual Meeting GlobeNewswire
Jun-10-20 10:04AM	Karyopharm Starts Dosing in Selinexor Study for Glioblastoma Zacks
Jun-09-20 09:00AM	Karyopharm Announces Dosing of First Patient in a Phase 1/2 Study of Selinexor in Combination with Standard of Care Therapy for Patients with Newly Diagnosed or Recurrent Glioblastoma GlobeNewswire -5.38%
Jun-03-20 08:32AM	Are Options Traders Betting on a Big Move in Karyopharm Therapeutics (KPTI) Stock? Zacks
Jun-01-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -7.41%
May-29-20 07:22AM	The Daily Biotech Pulse: ASCO Presentations Begin, Altimmune Pops On Insider Buying, Immutep Gets R&D Grant Benzinga
May-28-20 04:05PM	Karyopharm Reports Positive Phase 3 BOSTON Data in Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program GlobeNewswire
May-26-20 04:05PM	Karyopharm to Participate at Jefferies Virtual Healthcare Conference GlobeNewswire -6.59%
07:00AM	Karyopharm Announces Investor Conference Call to Discuss Phase 3 BOSTON Data To Be Presented at the American Society of Clinical Oncology 2020 Virtual Scientific Program GlobeNewswire
May-20-20 08:00AM	Karyopharm Submits Supplemental New Drug Application to FDA for XPOVIO® (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Line of Therapy GlobeNewswire +9.88%
May-13-20 08:00AM	Karyopharm Donates 60,000 Medical Masks Across Massachusetts and the United States in Partnership with Family Reach, Myeloma Crowd and The Leukemia & Lymphoma Society GlobeNewswire
May-12-20 07:00AM	Karyopharm to Participate at 2020 RBC Capital Markets Global Healthcare Virtual Conference GlobeNewswire -6.13%
May-06-20 08:07AM	Things Look Grim For Karyopharm Therapeutics Inc. (NASDAQ:KPTI) After Today's Downgrade Simply Wall St.
May-05-20 07:51PM	Were Hedge Funds Right About Karyopharm Therapeutics Inc (KPTI)? Insider Monkey -5.08%
05:30PM	Karyopharm Therapeutics Inc (KPTI) Q1 2020 Earnings Call Transcript Motley Fool
10:45AM	Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Misses Revenue Estimates Zacks
08:11AM	Recap: Karyopharm Therapeutics Q1 Earnings Benzinga
07:00AM	Karyopharm Reports First Quarter 2020 Financial Results and Highlights Recent Company Progress GlobeNewswire
May-04-20 08:53AM	Why Karyopharm (KPTI) Might Surprise This Earnings Season Zacks +6.93%
May-01-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -12.29%
Apr-30-20 01:03PM	PROMETRIKA and Karyopharm: Partners in Global COVID-19 Trial Business Wire
12:00PM	Top Ranked Momentum Stocks to Buy for April 30th Zacks
Apr-29-20 01:58PM	Karyopharm Announces Data from Phase 3 BOSTON Study Selected for Late-Breaking Oral Presentation at the American Society of Clinical Oncology 2020 Virtual Scientific Program GlobeNewswire
07:47AM	Should You Buy Stock Now in This New Coronavirus Drug Developer? Motley Fool
Apr-28-20 04:05PM	Karyopharm to Report First Quarter 2020 Financial Results on May 5, 2020 GlobeNewswire
Apr-27-20 12:00PM	What Makes Karyopharm Therapeutics (KPTI) a Strong Momentum Stock: Buy Now? Zacks
Apr-22-20 05:15PM	Karyopharm (KPTI) Bulls Find More Reasons to Smile SmarterAnalyst
09:08AM	Precision For Medicine Partners With Karyopharm Therapeutics To Initiate New Global Clinical Trial To Treat Patients With COVID-19 PR Newswire
07:09AM	Could a cancer drug treat coronavirus? Norton Healthcare joins global trial American City Business Journals
Apr-21-20 12:32PM	Karyopharm Starts Dosing With Selinexor for Coronavirus Infection Zacks -5.47%
Apr-20-20 08:55AM	Karyopharm Therapeutics Inc. (NASDAQ:KPTI): What Does Its Beta Value Mean For Your Portfolio? Simply Wall St. +6.87%
07:00AM	Karyopharm Announces Dosing of First Patient in Randomized Study Evaluating Low Dose Selinexor in Patients with Severe COVID-19 GlobeNewswire
Apr-07-20 07:00AM	Karyopharm to Evaluate Low Dose Selinexor as a Potential Treatment for Hospitalized Patients with COVID-19 GlobeNewswire
Apr-01-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -5.99%
Mar-24-20 04:23PM	Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch +10.78%
Mar-19-20 08:57AM	Karyopharm (KPTI): Strong Industry, Solid Earnings Estimate Revisions Zacks +18.09%
Mar-17-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +7.03%
Mar-12-20 07:00AM	Karyopharm Expands Executive Leadership Team with the Appointment of John Demaree as Chief Commercial Officer GlobeNewswire -12.85%
Mar-09-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire -13.03%
Mar-06-20 04:05PM	Karyopharm Therapeutics Announces Closing of Public Offering of Common Stock and Exercise in Full of Underwriters Option to Purchase Additional Shares GlobeNewswire
Mar-03-20 06:36PM	Karyopharm Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire -10.98%
09:53AM	Company News for Mar 3, 2020 Zacks
07:51AM	The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More Benzinga
Mar-02-20 04:11PM	This Biotech Stock Broke Out As A Cancer Drug 'Transforms' Its Story Investor's Business Daily +69.65%
04:01PM	Karyopharm Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire
12:57PM	Karyopharm's stock jumps on trial results for multiple myeloma combo candidate MarketWatch
07:00AM	Karyopharm Announces Phase 3 BOSTON Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Multiple Myeloma Following One to Three Prior Lines of Therapy GlobeNewswire
Feb-28-20 07:00AM	Karyopharm Appoints Richard Paulson to its Board of Directors GlobeNewswire +6.24%
Feb-27-20 08:43AM	Do Options Traders Know Something About Karyopharm (KPTI) Stock We Don't? Zacks +6.95%
Feb-20-20 09:16PM	Edited Transcript of KPTI earnings conference call or presentation 13-Feb-20 1:30pm GMT Thomson Reuters StreetEvents
Feb-19-20 08:00AM	U.S. Food and Drug Administration Accepts Karyopharms Supplemental New Drug Application for XPOVIO® (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma GlobeNewswire
Feb-18-20 07:03AM	Is Karyopharm Therapeutics Inc.'s (NASDAQ:KPTI) CEO Salary Justified? Simply Wall St. +6.24%
07:00AM	Karyopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-13-20 08:35AM	Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:00AM	Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress GlobeNewswire
Feb-11-20 07:00AM	Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO® (Selinexor) in Israel GlobeNewswire
Feb-10-20 10:20AM	What's in Store for Acorda (ACOR) This Earnings Season? Zacks
10:13AM	What's in Store for Ironwood (IRWD) This Earnings Season? Zacks
Feb-06-20 07:00AM	Karyopharm to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020 GlobeNewswire
Feb-03-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jan-22-20 09:33AM	3 Healthcare Stocks With Important Catalysts in Q1 TipRanks
Jan-20-20 08:45AM	Options Traders Expect Huge Moves in Karyopharm (KPTI) Stock Zacks
Jan-15-20 09:56AM	BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU Zacks
Jan-13-20 05:03PM	Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I Zacks -6.18%
09:13AM	Top Ranked Momentum Stocks to Buy for January 13th Zacks
07:00AM	Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update GlobeNewswire
Jan-08-20 11:23AM	Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics Zacks
Jan-07-20 09:03AM	5 Stocks With Recent Price Strength for Spectacular Returns Zacks
07:00AM	Karyopharm to Present at the 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-02-20 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Dec-24-19 07:24AM	The Daily Biotech Pulse: NewLink Genetics Licenses Ovarian Cancer Dug, Correvio Awaits FDA Verdict Benzinga
Dec-23-19 07:38AM	Karyopharm Submits New Drug Application to U.S. FDA for XPOVIO® (selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma GlobeNewswire
Dec-20-19 07:15AM	Is Karyopharm Therapeutics (NASDAQ:KPTI) Weighed On By Its Debt Load? Simply Wall St.
Dec-19-19 10:27AM	One particular field of drug development could dominate M&A in 2020 American City Business Journals
Dec-13-19 03:26PM	Hedge Funds Dropped The Ball On Karyopharm Therapeutics Inc (KPTI) Insider Monkey
Dec-09-19 07:25AM	There's A Really Good Chance You Missed One Of The Year's Best ETFs Benzinga
Dec-08-19 09:00AM	Karyopharm Presents XPOVIO® (Selinexor) and Eltanexor Data at the American Society of Hematology 2019 Annual Meeting GlobeNewswire
Dec-07-19 09:00AM	Karyopharm Reports New and Updated XPOVIO® (Selinexor) Data in Relapsed or Refractory Multiple Myeloma at the American Society of Hematology 2019 Annual Meeting GlobeNewswire
Dec-03-19 01:48PM	The Best-Performing ETF Has a Winning Strategy, But Just $29 Million Bloomberg
Dec-02-19 04:05PM	Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Nov-28-19 10:00AM	Are You Looking for a Top Momentum Pick? Why Karyopharm Therapeutics (KPTI) is a Great Choice Zacks
Nov-09-19 10:25PM	Edited Transcript of KPTI earnings conference call or presentation 4-Nov-19 1:30pm GMT Thomson Reuters StreetEvents
Nov-06-19 10:12AM	Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2019 Annual Meeting GlobeNewswire
08:52AM	Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4% Zacks
03:40AM	3 Names Making the Case That Investing in Small Biotech Is Never Dull TheStreet.com
Nov-05-19 06:53AM	The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga +6.38%
Nov-04-19 11:28AM	Karyopharm exceeds analyst expectations for first cancer drug launch Reuters +6.22%
08:25AM	Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates Zacks
07:00AM	Karyopharm Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress GlobeNewswire
Nov-03-19 10:51AM	The Week Ahead In Biotech: Smid-Cap Earnings Deluge, SITC Conference In The Spotlight Benzinga
Nov-01-19 04:58PM	Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire +7.18%
Oct-31-19 01:52PM	Did Hedge Funds Drop The Ball On Karyopharm Therapeutics Inc (KPTI)? Insider Monkey

Karyopharm Therapeutics Inc., a pharmaceutical company, engages in the discovery, development, and commercialization of various drugs directed against nuclear export and related targets for the treatment of cancer and other diseases. The company is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1. Its lead compound is XPOVIO (selinexor) tablets for the treatment of patients with heavily pretreated multiple myeloma. The company develops BOSTON, which is in Phase 3 clinical trial for the treatment of patients with multiple myeloma; STORM, which is in Phase 2b single-arm clinical trial for evaluating oral selinexor in combination with standard, low-dose dexamethasone in heavily pretreated patients, relapsed or refractory myeloma; STOMP, which is in Phase 1b/2 multi-arm clinical trial for the treatment of ow-dose dexamethasone plus standard therapies, including Velcade, Kyprolis, Revlimid, and Pomalyst or Darzalex; and SADAL, which is in Phase 2b clinical trial for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops SEAL, which is in Phase 3 clinical trial for the treartment of liposarcoma; SIENDO, which is in Phase 2/3 clinical trial for treatment of endometrial cancer; and KING, which is in Phase 2 for the treatment of glioblastoma multiforme brain tumor. In addition, the company has various investigational programs in clinical or preclinical development, such as Eltanexor (KPT-8602), KPT-9274, and Verdinexor (KPT-335). The company has collaboration with PROMETRIKA, LLC to conduct the first randomized clinical trial for low-dose selinexor (XPOVIOA), an XPO1 inhibitor, in hospitalized patients with severe COVID-19. Karyopharm Therapeutics Inc. was founded in 2008 and is headquartered in Newton, Massachusetts.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Shacham Sharon	President & CSO	Jun 22	Option Exercise	0.03	7,500	248	763,989	Jun 24 04:05 PM
Kauffman Michael	Chief Executive Officer	Jun 22	Option Exercise	0.03	7,500	248	763,989	Jun 24 04:07 PM
Shacham Sharon	President & CSO	Jun 22	Sale	20.00	7,500	150,000	756,489	Jun 24 04:05 PM
Kauffman Michael	Chief Executive Officer	Jun 22	Sale	20.00	7,500	150,000	756,489	Jun 24 04:07 PM
Shacham Sharon	President & CSO	Jun 15	Option Exercise	0.03	7,500	248	763,632	Jun 17 04:05 PM
Kauffman Michael	Chief Executive Officer	Jun 15	Option Exercise	0.03	7,500	248	763,632	Jun 17 04:07 PM
Shacham Sharon	President & CSO	Jun 15	Sale	16.37	7,500	122,779	756,489	Jun 17 04:05 PM
Kauffman Michael	Chief Executive Officer	Jun 15	Sale	16.37	7,500	122,779	756,489	Jun 17 04:07 PM
Shacham Sharon	President & CSO	Jun 10	Option Exercise	4.75	7,500	35,640	562,622	Jun 11 04:36 PM
Kauffman Michael	Chief Executive Officer	Jun 10	Option Exercise	4.75	7,500	35,640	562,622	Jun 11 04:39 PM
Shacham Sharon	President & CSO	Jun 10	Sale	18.13	7,500	135,944	555,122	Jun 11 04:36 PM
Kauffman Michael	Chief Executive Officer	Jun 10	Sale	18.13	7,500	135,944	555,122	Jun 11 04:39 PM
Shacham Sharon	President & CSO	Jun 09	Option Exercise	4.75	7,500	35,640	763,989	Jun 11 04:36 PM
Kauffman Michael	Chief Executive Officer	Jun 09	Option Exercise	4.75	7,500	35,640	763,989	Jun 11 04:39 PM
Shacham Sharon	President & CSO	Jun 09	Sale	18.50	7,500	138,746	756,489	Jun 11 04:36 PM
Kauffman Michael	Chief Executive Officer	Jun 09	Sale	18.50	7,500	138,746	756,489	Jun 11 04:39 PM
Shacham Sharon	President & CSO	May 18	Option Exercise	0.03	7,500	248	763,989	May 19 05:34 PM
Kauffman Michael	Chief Executive Officer	May 18	Option Exercise	0.03	7,500	248	763,989	May 19 05:36 PM
Shacham Sharon	President & CSO	May 18	Sale	20.00	7,500	150,000	756,489	May 19 05:34 PM
Kauffman Michael	Chief Executive Officer	May 18	Sale	20.00	7,500	150,000	756,489	May 19 05:36 PM
Shacham Sharon	President & CSO	May 15	Option Exercise	0.03	7,500	248	763,989	May 19 05:34 PM
Kauffman Michael	Chief Executive Officer	May 15	Option Exercise	0.03	7,500	248	763,989	May 19 05:36 PM
Shacham Sharon	President & CSO	May 15	Sale	18.65	7,500	139,841	756,489	May 19 05:34 PM
Kauffman Michael	Chief Executive Officer	May 15	Sale	18.65	7,500	139,841	756,489	May 19 05:36 PM
Shacham Sharon	President & CSO	May 07	Option Exercise	4.75	7,500	35,640	562,622	May 11 04:22 PM
Shacham Sharon	President & CSO	May 07	Option Exercise	4.75	7,500	35,640	763,989	May 11 04:22 PM
Kauffman Michael	Chief Executive Officer	May 07	Option Exercise	4.75	7,500	35,640	763,989	May 11 04:19 PM
Kauffman Michael	Chief Executive Officer	May 07	Option Exercise	4.75	7,500	35,640	562,622	May 11 04:19 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	May 07	Option Exercise	6.54	2,946	19,267	7,595	May 11 04:25 PM
Frenkel Ran	Chief Dev Operations Officer	May 07	Sale	20.00	1,974	39,480	35,088	May 11 04:26 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	May 07	Sale	19.73	9,660	190,627	4,649	May 11 04:25 PM
Shacham Sharon	President & CSO	May 07	Sale	19.63	7,500	147,209	555,122	May 11 04:22 PM
Shacham Sharon	President & CSO	May 07	Sale	19.63	7,500	147,205	756,489	May 11 04:22 PM
Kauffman Michael	Chief Executive Officer	May 07	Sale	19.63	7,500	147,205	756,489	May 11 04:19 PM
Kauffman Michael	Chief Executive Officer	May 07	Sale	19.63	7,500	147,209	555,122	May 11 04:19 PM
Shacham Sharon	President & CSO	Apr 09	Option Exercise	4.75	10,000	47,520	565,122	Apr 10 05:06 PM
Kauffman Michael	Chief Executive Officer	Apr 09	Option Exercise	4.75	10,000	47,520	565,122	Apr 10 05:09 PM
Kauffman Michael	Chief Executive Officer	Apr 09	Sale	20.64	10,000	206,404	555,122	Apr 10 05:09 PM
Shacham Sharon	President & CSO	Apr 09	Sale	20.64	10,000	206,404	555,122	Apr 10 05:06 PM
Shacham Sharon	President & CSO	Apr 08	Option Exercise	4.75	10,000	47,520	766,489	Apr 10 05:06 PM
Kauffman Michael	Chief Executive Officer	Apr 08	Option Exercise	4.75	10,000	47,520	766,489	Apr 10 05:09 PM
Kauffman Michael	Chief Executive Officer	Apr 08	Sale	18.61	10,000	186,115	756,489	Apr 10 05:09 PM
Shacham Sharon	President & CSO	Apr 08	Sale	18.61	10,000	186,115	756,489	Apr 10 05:06 PM
Greene Barry E	Director	Mar 13	Option Exercise	0.03	3,030	100	6,030	Mar 17 05:35 PM
Kauffman Michael	Chief Executive Officer	Mar 10	Option Exercise	4.75	10,000	47,520	565,122	Mar 11 07:07 PM
Shacham Sharon	President & CSO	Mar 10	Option Exercise	4.75	10,000	47,520	565,122	Mar 11 07:10 PM
Shacham Sharon	President & CSO	Mar 10	Sale	22.22	10,000	222,186	555,122	Mar 11 07:10 PM
Kauffman Michael	Chief Executive Officer	Mar 10	Sale	22.22	10,000	222,186	555,122	Mar 11 07:07 PM
Kauffman Michael	Chief Executive Officer	Mar 09	Option Exercise	4.75	10,000	47,520	766,489	Mar 11 07:07 PM
Shacham Sharon	President & CSO	Mar 09	Option Exercise	4.75	10,000	47,520	766,489	Mar 11 07:10 PM
Shacham Sharon	President & CSO	Mar 09	Sale	22.52	10,000	225,195	756,489	Mar 11 07:10 PM
Kauffman Michael	Chief Executive Officer	Mar 09	Sale	22.52	10,000	225,195	756,489	Mar 11 07:07 PM
Mirza Mansoor Raza	Director	Mar 02	Option Exercise	8.06	5,000	40,300	5,000	Mar 04 06:51 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Mar 02	Option Exercise	10.39	26,500	275,335	36,867	Mar 04 08:33 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Mar 02	Sale	25.37	26,500	672,279	10,367	Mar 04 08:33 PM
Mirza Mansoor Raza	Director	Mar 02	Sale	23.50	5,000	117,500	0	Mar 04 06:51 PM
Frenkel Ran	Chief Dev Operations Officer	Feb 19	Sale	16.48	2,975	49,034	36,066	Feb 21 05:57 PM
Shah Jatin	EVP, Chief Medical Officer	Feb 19	Sale	16.48	1,375	22,663	40,759	Feb 21 05:58 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Feb 19	Sale	16.48	2,961	48,803	10,367	Feb 21 05:55 PM
Shacham Sharon	President & CSO	Feb 19	Sale	16.48	8,817	145,321	555,122	Feb 21 05:54 PM
Shacham Sharon	President & CSO	Feb 19	Sale	16.48	8,817	145,321	756,489	Feb 21 05:54 PM
Kauffman Michael	Chief Executive Officer	Feb 19	Sale	16.48	8,817	145,321	756,489	Feb 21 05:53 PM
Kauffman Michael	Chief Executive Officer	Feb 19	Sale	16.48	8,817	145,321	555,122	Feb 21 05:53 PM
Kauffman Michael	Chief Executive Officer	Feb 11	Option Exercise	4.75	10,000	47,520	552,139	Feb 12 04:20 PM
Shacham Sharon	President & CSO	Feb 11	Option Exercise	4.75	10,000	47,520	552,139	Feb 12 04:21 PM
Kauffman Michael	Chief Executive Officer	Feb 11	Sale	17.43	10,000	174,294	542,139	Feb 12 04:20 PM
Shacham Sharon	President & CSO	Feb 11	Sale	17.43	10,000	174,294	542,139	Feb 12 04:21 PM
Kauffman Michael	Chief Executive Officer	Feb 10	Option Exercise	4.75	10,000	47,520	753,506	Feb 12 04:20 PM
Shacham Sharon	President & CSO	Feb 10	Option Exercise	4.75	10,000	47,520	753,506	Feb 12 04:21 PM
Shacham Sharon	President & CSO	Feb 10	Sale	16.93	10,000	169,327	743,506	Feb 12 04:21 PM
Kauffman Michael	Chief Executive Officer	Feb 10	Sale	16.93	10,000	169,327	743,506	Feb 12 04:20 PM
Shacham Sharon	President & CSO	Jan 09	Option Exercise	4.75	10,000	47,520	552,139	Jan 10 05:04 PM
Kauffman Michael	Chief Executive Officer	Jan 09	Option Exercise	4.75	10,000	47,520	552,139	Jan 10 05:07 PM
Mirza Mansoor Raza	Director	Jan 09	Option Exercise	8.06	2,056	16,571	2,056	Jan 13 05:02 PM
Mirza Mansoor Raza	Director	Jan 09	Sale	20.00	2,056	41,120	0	Jan 13 05:02 PM
Kauffman Michael	Chief Executive Officer	Jan 09	Sale	19.19	10,000	191,880	542,139	Jan 10 05:07 PM
Shacham Sharon	President & CSO	Jan 09	Sale	19.19	10,000	191,880	542,139	Jan 10 05:04 PM
Shacham Sharon	President & CSO	Jan 08	Option Exercise	4.75	10,000	47,520	753,506	Jan 10 05:04 PM
Kauffman Michael	Chief Executive Officer	Jan 08	Option Exercise	4.75	10,000	47,520	753,506	Jan 10 05:07 PM
Kauffman Michael	Chief Executive Officer	Jan 08	Sale	18.57	10,000	185,705	743,506	Jan 10 05:07 PM
Shacham Sharon	President & CSO	Jan 08	Sale	18.57	10,000	185,705	743,506	Jan 10 05:04 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Dec 27	Option Exercise	10.39	5,000	51,950	8,653	Dec 31 09:06 AM
Mirza Mansoor Raza	Director	Dec 27	Option Exercise	8.06	2,944	23,729	2,944	Dec 31 09:15 AM
Mirza Mansoor Raza	Director	Dec 27	Sale	20.00	2,944	58,880	0	Dec 31 09:15 AM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Dec 27	Sale	20.00	5,000	100,000	3,653	Dec 31 09:06 AM
Mirza Mansoor Raza	Director	Dec 18	Option Exercise	1.49	12,121	18,000	12,121	Dec 20 04:04 PM
Mirza Mansoor Raza	Director	Dec 18	Sale	17.18	12,121	208,236	0	Dec 20 04:04 PM
Shacham Sharon	President & CSO	Dec 10	Option Exercise	4.75	10,000	47,520	539,767	Dec 11 05:21 PM
Kauffman Michael	Chief Executive Officer	Dec 10	Option Exercise	4.75	10,000	47,520	539,767	Dec 11 05:24 PM
Kauffman Michael	Chief Executive Officer	Dec 10	Sale	15.99	10,000	159,896	529,767	Dec 11 05:24 PM
Shacham Sharon	President & CSO	Dec 10	Sale	15.99	10,000	159,896	529,767	Dec 11 05:21 PM
Shacham Sharon	President & CSO	Dec 09	Option Exercise	4.75	10,000	47,520	741,134	Dec 11 05:21 PM
Kauffman Michael	Chief Executive Officer	Dec 09	Option Exercise	4.75	10,000	47,520	741,134	Dec 11 05:24 PM
Mirza Mansoor Raza	Director	Dec 09	Option Exercise	5.64	10,342	58,360	10,342	Dec 11 05:26 PM
Mirza Mansoor Raza	Director	Dec 09	Sale	17.02	10,342	176,034	0	Dec 11 05:26 PM
Kauffman Michael	Chief Executive Officer	Dec 09	Sale	17.02	10,000	170,210	731,134	Dec 11 05:24 PM
Shacham Sharon	President & CSO	Dec 09	Sale	17.02	10,000	170,210	731,134	Dec 11 05:21 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Dec 06	Option Exercise	8.47	10,000	84,650	16,653	Dec 10 05:18 PM
Primiano Christopher Brett	EVP, CBO, GC & Secretary	Dec 06	Sale	17.45	13,000	226,908	3,653	Dec 10 05:18 PM
Shacham Sharon	President & CSO	Nov 11	Option Exercise	4.75	10,000	47,520	539,767	Nov 12 04:34 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience